Ferring Pharmaceuticals Inc., a global biopharmaceutical company, is headquartered in the United States and operates extensively across Europe, Asia, and Latin America. Founded in 1950, Ferring has established itself as a leader in reproductive health, urology, and gastroenterology, focusing on innovative therapies that address unmet medical needs. The company is renowned for its core products, including hormone therapies and treatments for various gastrointestinal disorders, which are distinguished by their patient-centric approach and commitment to research and development. Ferring's dedication to advancing healthcare has positioned it as a notable player in the biopharmaceutical industry, with significant achievements in clinical research and a robust pipeline of therapies aimed at improving patient outcomes.
How does Ferring Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ferring Pharmaceuticals Inc.'s score of 34 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ferring Pharmaceuticals Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Ferring Holding SA, which may influence its climate commitments and reporting practices. Ferring Pharmaceuticals has not established specific reduction targets or initiatives, as there are no documented SBTi (Science Based Targets initiative) or CDP (Carbon Disclosure Project) reduction targets available. This lack of data suggests that the company may still be in the early stages of developing its climate strategy. As a subsidiary, Ferring Pharmaceuticals may align its climate commitments with those of its parent company, Ferring Holding SA. However, without specific emissions data or reduction targets, it is challenging to assess the company's current impact on climate change or its future commitments. In summary, Ferring Pharmaceuticals Inc. has not disclosed any carbon emissions data or specific climate commitments, reflecting a potential area for development in their sustainability strategy.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ferring Pharmaceuticals Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.